GET DAILY SIGNALSAmerican Shared Hospital Services (AMS) Delivers Q3 Revenue Growth but Faces EPS Miss During Strategic Shift
Key Takeaways
- Third-quarter 2026 revenue rose 6% year over year to approximately $7.6 million, missing analyst consensus estimates.
- The company reported a GAAP net loss of $0.09 per share, versus a consensus expectation of a $0.01 profit.
- Direct Patient Services revenue increased 14% in the quarter, while nine-month revenue climbed 14% to roughly $23.1 million.
- Nine-month operating cash flow reached about $5.8 million, lifting cash, equivalents, and restricted cash to roughly $9.5 million.
- Adjusted EBITDA declined to about $1.4 million from $1.9 million a year earlier, while gross margin narrowed.
- The company issued no formal guidance, and first patient treatments at its San Javier joint venture are now targeted for mid-2027.
Earnings Context and Its Significance
American Shared Hospital Services (AMS) provides turnkey radiation therapy and stereotactic radiosurgery solutions, including Gamma Knife and proton beam systems, through equipment leasing and direct patient services. The third-quarter report stands out because the company has been shifting from a leasing-focused model toward higher-recurring Direct Patient Services revenue while also working to strengthen its balance sheet. After a second quarter that featured 19% revenue growth, investors sought confirmation in Q3 that momentum could hold as management handled lender discussions with Fifth Third Bank. These results matter because they test whether the growth strategy and improving cash generation can align with a forbearance agreement, refinancing efforts, and a series of capital-intensive expansion projects.
Reported Results
For the third quarter ended September 30, 2026, AMS reported revenue of approximately $7.62 million, a 6% increase from $7.17 million in the prior-year period. The top line fell short of consensus estimates of roughly $8.5 million to $8.6 million. The company posted a GAAP net loss of $0.09 per diluted share, missing analyst expectations of a $0.01 per share profit.
Direct Patient Services revenue grew 14% in the quarter, while Medical Equipment Leasing revenue declined modestly. For the nine-month period, total revenue increased 14% to about $23.1 million, driven by a 27% rise in Direct Patient Services revenue. Gross margin narrowed to 19.9% from 22.1% a year earlier, reflecting higher costs of revenue and elevated selling and administrative expenses tied in part to the credit agreement amendment. Adjusted EBITDA declined to approximately $1.4 million from $1.9 million.
On the balance sheet, the company reported meaningful liquidity improvement. Nine-month operating cash flow totaled about $5.8 million, and cash, equivalents, and restricted cash reached roughly $9.5 million, up from $6.8 million at mid-year. The current portion of long-term debt decreased to $15.7 million from $17.3 million at year-end 2025. Management also disclosed a $2.0 million subordinated financing from an entity controlled by the Executive Chairman, alongside a Third Amendment and Forbearance Agreement with Fifth Third Bank. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Heading into the report, sentiment had already cooled from the second quarter, when shares traded higher following stronger revenue growth. The third-quarter miss, combined with a sequential revenue decline from $8.4 million in Q2 and a widening loss, weighed on investor confidence. The slowdown in Direct Patient Services growth, a decline in proton beam treatment volumes, and another increase in the allowance for credit losses on Rhode Island receivables reinforced concerns that the quarter lost momentum even as liquidity improved.
At the same time, the strengthening cash position and reduced near-term debt were viewed as important offsets. Investors appear to be balancing disappointment over top-line softness and margin compression against evidence that the company is generating cash and extending its financial runway. The absence of formal guidance left the market to interpret the sustainability of growth and the progress of refinancing efforts on its own.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will focus on whether AMS can reaccelerate revenue growth while preserving the cash generation that characterized the first nine months of 2026. The company’s Direct Patient Services segment remains the primary growth engine, but its pace slowed sharply from the second quarter, making the next few quarters important for gauging demand trends and utilization across Rhode Island and international facilities.
Balance sheet execution will stay central to the story. The forbearance agreement with Fifth Third Bank runs through June 30, 2027, and management continues to evaluate longer-term capital structure alternatives. Investors will monitor whether the company can refinance its debt, manage the current portion of long-term debt, and avoid dilutive outcomes, given that cash still covers only a portion of near-term obligations.
On the operational side, key factors include Gamma Knife procedure volumes, which showed strength domestically and internationally, and proton beam treatment fractions, which management attributed to normal cyclicality after a third-quarter dip. The San Javier joint venture in Guadalajara, now targeting first patient treatments in mid-2027, and the planned Rhode Island expansion projects represent longer-dated catalysts. Cost control, margin recovery, and any further credit-loss provisions tied to receivables will also shape how investors assess the path back to profitability. From what I see, the company’s ability to navigate these elements will determine longer-term investor interest.
Using Tickeron AI Tools for Deeper Analysis
In my view, tools like Tickeron’s AI-powered platforms can help investors quickly compare AMS against peers and spot relevant patterns without spending hours on manual research. I often turn to the AI Screener when evaluating healthcare names like this one, as it lets me filter by fundamentals, technical signals, and industry trends in one place. It has become a regular part of how I review quarterly results and identify comparable setups across sectors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for AMS turns negative, indicating new downward trend
AMS saw its Momentum Indicator move below the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 138 similar instances where the indicator turned negative. In 97 of the 138 cases, the stock moved further down in the following days. The odds of a decline are at 70%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for AMS turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 32 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
The Aroon Indicator for AMS entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for AMS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMS advanced for three days, in 127 of 200 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
AMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.334) is normal, around the industry mean (204.532). P/E Ratio (-4.462) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (2.498). Dividend Yield (0.164) settles around the average of (0.154) among similar stocks. P/S Ratio (0.313) is also within normal values, averaging (2.688).
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. AMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provideer of turnkey technology solutions for advanced radio surgical and radiation therapy services
Industry HospitalNursingManagement
Advertisement